Welcome back, everyone. We hope your weekend was pleasant. We had a soggy time here on the Pharmalot corporate campus, where the rains overwhelmed us. Now, though, we are drying out and brewing a cup of stimulation to jumpstart the day. To help you along, we have found a few interesting items. Stay in touch...
FDA Delays Approval Of Lilly, Amylin Diabetes Drug (Reuters)
Pet Owners Sue Over Flea Meds (The Morning Call)
Abbott's TriCor Fails To Beat Placebo (Forbes)
Merck Urged To Lower Isentress Price (SouthFloridaGayNews)
Court Rules Against Autism Vaccine Claims (Reuters)
Genetix Gets $35M For Gene Therapy Work (Xconomy)
6 Comments
Good Morning Ed,
It is 9:35am, sunny, and 70 degrees down here in NC. Gonna load up my grandson and his little red wagon, and venture out to the local nurseries for some new landscaping ideas.
Hope all in NJ dry out very soon. If not, invest in row boats.
This delay can't be good for Amylin. The market is getting increasingly competitive and time is costing them very valuable market share.
A huge blow for Abbott and confirmation that tricor is over promoted over prescribed and over priced.
I worked for a company whose entry into the fenofibrate market was blocked by Abbott's perversion of patent law with Tricor. As far as I am concerned, this is payback time.
Dog owners should switch to Frontline (fibronil) for flea/tick protection. I've used it on my dogs for long as the product has been marketed, with no adverse effects.
Could someone please explain to me what is a "Free Range Aspergian Male". I saw the term in the bio of one of the board members of Autism Speaks.